BMO Capital Initiates Coverage On Genmab with Market Perform Rating, Announces Price Target of $34.73

BMO Capital analyst Etzer Darout initiates coverage on Genmab (NASDAQ:GMAB) with a Market Perform rating and announces Price Target of $34.73.

BMO Capital analyst Etzer Darout initiates coverage on Genmab (NASDAQ:GMAB) with a Market Perform rating and announces Price Target of $34.73.

Total
0
Shares
Related Posts